Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss (5-15%) and improve cardiometabolic risk factors in adults with obesity, with efficacy increasing with higher doses.
If lifestyle changes alone haven't led to significant weight loss, GLP-1 or dual agonist medications can help you lose 5-15% of your body weight and improve your blood sugar and heart health. These are prescription medications that work by mimicking hormones that control hunger. You will need to start with a low dose and slowly increase it to avoid stomach side effects like nausea.
Saxenda® 3.0 mg... confirmed significant average weight loss... SCALE Obesity and Prediabetes study 8.0% [placebo 2.6%]... STEP 1... semaglutide 2.4 mg... average 12.4% weight loss... SURPASS-1... tirzepatide 5 mg, 10 mg, 15 mg... HbA1c reduction 1.91%, 1.93%, 2.11%
Why this rating
Multiple large-scale, randomized, placebo-controlled Phase 3 clinical trials (EQUIP, CONQUER, SCALE, STEP, SURPASS) are cited.
Source
Recent Advances in Anti-Obesity Drugs
Jang Won Son · Journal of Korean Diabetes · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →